1. Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada;
2. Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD;
3. Molecular Characterization Laboratory, Leidos Medical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD;
4. Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD;
5. Institute of Pathology, University of Wuerzburg, Wuerzburg, Germany;
6. Department of Pathology, Hospital Clínic, Barcelona, Spain;
7. Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE;
8. Department of Immunology and Centre for Cancer Biomedicine, University of Oslo and Oslo University Hospital, Oslo, Norway;
9. Department of Pathology, Oregon Health and Sciences University, Portland, OR;
10. Department of Clinical Pathology, Robert-Bosch-Krankenhaus and Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany;
11. Oslo University Hospital, Oslo, Norway;
12. Clinical Pathology, Cleveland Clinic Foundation, Cleveland, OH;
13. Department of Molecular Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, OH;
14. Department of Pathology, City of Hope, Duarte, CA;
15. Department of Pathology, University of Arizona, Tucson, AZ;
16. Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; and
17. Department of Pathology, British Columbia Cancer Agency, Vancouver, BC, Canada